Genprex, Inc.
GNPXNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for GNPX. That does not mean none is planned.
Get an email about GNPX's next catalysts
Track Genprex (GNPX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (earnings).See the timeline
1 upcoming, 0 past
GNPX Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | FQ end Sep/2026 | Call: tbd
Market Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
quaratusugene ozeplasmid | Phase 2 | Carcinoma, Non-Small Cell Lung | - | - |
Frequently asked questions
What is in Genprex, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Genprex, Inc.'s (GNPX) pipeline across Phase 2. Its lead program is quaratusugene ozeplasmid (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Genprex, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Genprex, Inc. (GNPX) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track GNPX biotech catalysts?→
Add GNPX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Genprex, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.